Skip to content
Integrated Report 2021
Click to view online
Click to download
Annual Financial Statements 2021
Click to download
Integrated Report 2021
Click to view online
Click to download
Annual Financial Statements 2021
Click to download

ABOUT ASPEN

 

Headquartered in Durban, South Africa, we are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.

With an acknowledged presence of more than two decades in the pharmaceutical sector, we improve the health of patients in more than 150 countries. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands.

SENS ANNOUNCEMENTS

INVESTOR CALENDAR

09
December 2021
Annual General Meeting

LATEST RESULTS

Regional
Overviews

AFRICA MIDDLE EAST

AMERICAS

ASIA

AUSTRALASIA

EUROPE CIS

Africa Middle East

This region represents the single largest revenue contributor in the Commercial Pharmaceuticals segment, with revenues predominantly from Regional Brands. Aspen supplies well-established local brands, as well as internationally recognised medicines across multiple countries in the region, supported by commercial and sales employees. Extensive and differentiated manufacturing capabilities including high potency and hormonal solids, vaccines and other state-of-the-art sterile capabilities exist at one of the Group’s primary manufacturing sites in Gqeberha, South Africa. This primary site is complemented by five regional sites across the continent.

Key countries
Egypt
Kenya
Kingdom of Saudi Arabia
South Africa
Tanzania
Number of products launched:
48
(2020: 29)

 

The South African private pharmaceutical sector was valued at R49,8 billion MAT* for the period ended July 2021.

In South Africa, four out of the top 15 brands in the private sector were Aspen products.

Source: IQVIA, IQVIA Midas 2021 and Market Prognosis Global. South Africa and Middle East and North Africa only.
Sub-Saharan Africa (“SSA”) not covered by IQVIA

*MAT = Moving annual total

Americas

Aspen’s presence in the Americas is dominated by the businesses in Latin America. Mexico and Brazil are the largest contributors to regional performance. Aspen provides a range of trusted brands across prescription, hospital and over-the-counter medicines and operates one finished dose form manufacturing facility in Brazil.

Key countries
Brazil
Canada
Chile
Colombia
Ecuador
Mexico
USA
Number of products launched:
3
(2020: 8)

 

The Mexican pharmaceutical market grew 14,0% to USD10,8 billion MAT* June 2021, positively impacted by double-digit growth across the generic and ethical markets.

Pharmaceutical sales across the total Spanish Latin America market grew 20% to USD21,3 billion MAT June 2021.

Source: IQVIA – June 2021
*MAT = Moving annual total

Asia

This region comprises all Asian territories where we sell products, including China. Active trading subsidiaries include those in China, the Philippines, Taiwan and Malaysia with other countries in the region reached via distributors. Sterile Focus Brands are the key contributor to revenue. Our manufacturing facility in India is our primary new product development site.

Key countries
China
Malaysia
Philippines
Singapore
Taiwan
Number of products launched:
3
(2020: 1)

 

The Chinese general anaesthesia therapy area consists of inhalation and intravenous products. The propofol market grew 10,6% year-on-year MAT* May 2021.

The South Korean pharmaceutical market is forecast to grow at a CAGR of 6% between 2019 and 2024, reaching Won24,579 billion by 2024.

Source: China IMS CHPA Report, May 2021.
*MAT = Moving annual total

Source: China IMS CHPA Report, May 2021.
*MAT = Moving annual total

Australasia

One of the largest pharmaceutical companies in the Australasia region, with a comprehensive portfolio of medicines comprising Regional Brands, including prescription and over-the-counter products, as well as Sterile Focus Brands. A widely-accredited manufacturing facility is operated in Australia, producing finished dose form solids, liquids and semi-solids as well as packaging for third party contract manufacturing for domestic and export markets.

Key countries
Australia
New Zealand
Number of products launched:
2
(2020: 2)

 

The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was valued at AUD20,7 billion MAT* to May 2021.

Source: IQVIA – August 2020
*MAT = Moving annual total

Europe CIS

Europe CIS provides a broad range of Sterile Focus and Regional Brands while operating a range of manufacturing facilities for Aspen’s own production needs, as well as manufacturing for third parties. Sterile Focus Brands comprise anaesthetics and thrombosis in Russia and the other CIS countries only. Manufacturing activities include active pharmaceutical ingredients and finished dose form production and our sites are widely accredited. The prefilled syringe and multi-dose form sites in France and Germany respectively, provide finished dose form medicines for commercialisation by Aspen and third parties for both domestic and export markets.

Key countries
France
Germany
Netherlands
Russian Federation
United Kingdom
Number of products launched:
1
(2020: Nil)

 


Scroll To Top